FDA Grants Breakthrough Designation to VT Ablation System
The pulsed field ablation technology for ventricular tachycardia has been granted FDA Breakthrough Device Designation and accepted into the TAP pilot program.
The pulsed field ablation technology for ventricular tachycardia has been granted FDA Breakthrough Device Designation and accepted into the TAP pilot program.
The clearance broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.
Dr. Steven Abramowitz at MedStar Washington Hospital Center has successfully performed the world’s first deep venous stent thrombectomies using an innovative minimally invasive catheter. The thrombectomy catheter, known as the “stent cleaner,” has shown exceptional procedural success rates, improving symptoms and offering a promising treatment option for patients with deep venous stent thrombosis.
Read More